Sequence effect of Irinotecan and Fluoruracil treatment on Pharmacokinetics and Toxicity in chemotherapy naive metastatic colorectal cancer patients.
Articolo
Data di Pubblicazione:
2001
Citazione:
Sequence effect of Irinotecan and Fluoruracil treatment on Pharmacokinetics and Toxicity in chemotherapy naive metastatic colorectal cancer patients / A., Falcone; A., Di Paolo; G. L., Masi; G., Allegrini; R., Danesi; M., Lencioni; E., Pfanner; S., Comis; M., Del Tacca; Conte, Pierfranco. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - STAMPA. - 19:15(2001), pp. 3456-3462. [10.1200/JCO.2001.19.15.3456]
Abstract:
To investigate the sequence effect of irinotecan and a 48-hour infusion of fluorouracil (5-FU) modulated by leucovorin (LV) on the plasma pharmacokinetics of irinotecan and its metabolites, the toxicity profile of this combination, and irinotecan's maximum-tolerated dose (MTD). PATIENTS AND METHODS: Thirty-three metastatic colorectal cancer patients were randomized to receive a 60-minute infusion of irinotecan before or after a 48-hour infusion of 5-FU modulated by LV. The reverse sequence was used after 21 days for the second cycle. 5-FU 3,500 mg/m2 was preceded by l-LV 250 mg/m2. Irinotecan 150 mg/m2 (starting dose) was administered to the first three patients. The dose was escalated by 50 mg/m2 in subsequent groups of three to six patients to determine the MTD for both sequences. Pharmacokinetic analysis of irinotecan and its metabolites was performed after each cycle. RESULTS: Toxicities were affected by the sequence of administration of irinotecan and 5-FU, with an improved tolerability for irinotecan followed by 5-FU. The irinotecan MTD was reached at 300 mg/m2 when irinotecan followed 5-FU and at 450 mg/m2 when it preceded 5-FU. In seven of 23 patients who received both sequences at identical irinotecan doses, the dose-limiting toxicity was observed only when irinotecan followed 5-FU. Pharmacokinetic analysis revealed that the administration sequence significantly affected the SN-38 area under the concentration-versus-time curve (AUC), which was 40.1% lower (P <.05) when irinotecan preceded 5-FU. CONCLUSION: The sequence of treatment with irinotecan and infusional 5-FU affects the tolerability of this combination. This can be explained in part by a reduced SN-38 AUC when irinotecan preceded infusional 5-FU. Well-defined 5-FU/irinotecan regimens are needed because the administration sequence or the interval between the agents might affect treatment tolerance and perhaps also activity.
Tipologia CRIS:
Articolo su rivista
Keywords:
Irinotecan and Fluoruracil; Pharmacokinetics; colorectal cancer
Elenco autori:
A., Falcone; A., Di Paolo; G. L., Masi; G., Allegrini; R., Danesi; M., Lencioni; E., Pfanner; S., Comis; M., Del Tacca; Conte, Pierfranco
Link alla scheda completa:
Pubblicato in: